GlobeNewswire Inc.··Hagens BermanGene Therapy Firm uniQure Faces Securities Lawsuit Over Alleged FDA Data Distortion
Hagens Berman investigates $QURE for misrepresenting FDA interactions on gene therapy AMT-130. Stock crashed 49% after FDA publicly rebuked company's data claims.
QUREinvestor lossessecurities class action